A growing body of evidence indicates that genetic factors are involved in an increased risk of infection. We investigated whether mannose-binding lectin (MBL) gene polymorphisms that cause low levels of MBL are associated with the occurrence of major infections in patients, mainly bearing hematological malignancies, after high-dose chemotherapy (HDT) rescued by autologous peripheral blood stem cell transplantation (auto-PBSCT). A retrospective evaluation of 113 patients treated with HDT and auto-PBSCT revealed that the low-producing genotypes, B/B and B/LXA, were associated with major bacterial infection (P ¼ 0.0016, OR 7.9). We next performed a nation-wide large-scale study to assess the allele frequency of the MBL coding mutation in a total of 2623 healthy individuals in Japan. The frequency of allele B was estimated to be B0.2, almost the same in seven different areas of Japan. This common occurrence suggests that MBL deficiency may play an important role in the clinical settings of immunosuppression. Genes and Immunity (2005) The carbohydrate recognition domain of MBL binds to high mannose and N-acetyl-glucosamine oligosaccharides on various microorganisms, while the collagen-like domain is considered to bind to its receptors on phagocytes.
Mannose-binding lectin (MBL), also called mannanbinding lectin, is a member of the collectin family of proteins, characterized by the presence of collagen-like domains and carbohydrate recognition lectin domains. 1, 2 The carbohydrate recognition domain of MBL binds to high mannose and N-acetyl-glucosamine oligosaccharides on various microorganisms, while the collagen-like domain is considered to bind to its receptors on phagocytes. 1, 3 MBL activates complement independently of antibodies, which is a third pathway (lectin pathway) distinct from the classical and alternative complement activation cascade. It is therefore considered that MBL is an apical and important component of innate immunity of host defense. MBL has been shown to bind to a wide range of microorganisms including fungi, bacteria, protozoa, and viruses. 4 The serum level of MBL is dependent on various factors such as polymorphisms (in the coding region) and ethnicity and age (in the promoter region). [5] [6] [7] Of these factors, the structural polymorphisms at codons 52, 54, and 57 in the coding region are the most important determinants. All the three polymorphisms are caused by a single amino-acid substitution and result in the profound decrease of serum MBL in the individuals carrying the polymorphisms homozygously. Two polymorphisms in the promoter region at positions À550 and À221 also have additional, but less pronounced effects on the serum level of MBL. 5 Individuals carrying either of these three codon variants homozygously are common in different ethnic groups from 5 to 10%. 4 MBL deficiency is associated with infection in infants with immature immunity, 8, 9 and patients with autoimmune disorders 10 and cystic fibrosis. 11, 12 An association of MBL deficiency and infection is also reported in patients treated with conventional chemotherapy 13, 14 or high-dose myeloablative chemotherapy followed by allogeneic stem cell transplantation, 15 which is not confirmed by others. 16, 17 In the present study, we report an increased risk of major bacterial infection in patients carrying the MBL polymorphism when treated with high-dose chemotherapy (HDT) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). In addition, the allele frequencies of the MBL polymorphism in a total of 2623 healthy individuals were determined in seven different areas in Japan, which is, to our knowledge, the largest scale of study for MBL polymorphism in a single ethnic group.
In all, 113 patients treated with HDT and auto-PBSCT between 1990 and 2002 in Kyushu University Hospital were analyzed for clinical records and MBL genotypes. This study was approved by the Institutional Review Board of Kyushu University Hospital. Diagnoses were non-Hodgkin's lymphoma in 66 patients, acute myeloid leukemia in 25, acute lymphoid leukemia in 10, Hodgkin's lymphoma in 6, multiple myeloma in 4, neuroblastoma in 1, and synovial sarcoma in 1. All patients received autotransplantation of peripheral blood stem cells (PBSC) without any manipulation. The number of infused PBSC was 2 Â 10 6 CD34-positive cells/kg or more. Most of the patients were treated with standard regimens for non-Hodgkin's lymphoma (ranimustine (MCMU), carboplatin (CBDCA), etoposide (VP-16), cyclophosphamide), acute myeloid leukemia (busulfan, etoposide, cytarabine), Hodgkin's lymphoma (ranimustine (MCMU), carboplatin (CBDCA), etoposide (VP-16), cyclophosphamide), acute lymphoid leukemia (busulfan, etoposide, cytarabine), and multiple myeloma (total body irradiation (TBI) þ melphalan (L-PAM)). A major infection was defined as a microbiologically confirmed systemic or disseminated infection as described. 15 The episodes of major infection occurred within 100 days after auto-PBSCT were analyzed in this study. All patients received intensive supportive care, including isolation in high-energy particulate-airfiltered rooms, prophylactic antimicrobials including oral ciplofloxacin 600 mg/day, oral fluconazole 400 mg/day, intravenous acyclovir 250 mg/day, and oral cotrimoxazole 1920 mg/day. Intravenous antibiotics, amphotericin B and G-CSF, were administered during a febrile neutropenic period. Out of 113 patients treated with HDT and auto-PBSCT, 16 major episodes of infection including sepsis (seven patients), bacterial pneumonia (two patients), bacterial meningitis (one patient), adenoviral cystitis (two patients), pulmonary aspergillosis (three patients), and Pneumocystis pneumonia (one patient) were noted. Two patients experienced two major infections. One patient had both adenoviral cystitis and pulmonary aspergillosis, while the other experienced both sepsis and pulmonary aspergillosis.
According to the results of polymerase chain reaction/ single-strand conformation polymorphism analysis 18 and subsequent nucleotide sequencing, only Gly to Asp substitution at codon 54 (G54D, designated allele B) was identified in our patients. There were no polymorphisms at codons 52 and 57 (allele D and C, respectively). The normal MBL allele is named A. As shown in Table 1 , eight patients were homozygous for G54D variant (B/B), 30 carried G54D heterozygously (B/ A), and the remaining 75 were homozygous for normal allele (A/A). The genotypes of the À550 (H/L variants) and À221 (X/Y variants) of the promoter region of the MBL gene are also shown in Table 1 . The designations of these variants in the coding region and promoter region are based on the nomenclature of previous reports. 19 In total, 28 patients were carrying H/H allele, 47 were carrying H/L, and 38 were carrying L/L, while X/Y allele was identified in 20 patients and Y/Y allele in 93. The allele frequencies of the positions at -550, À221 and codon 54 were almost the same compared to those Insufficient vs sufficient (both bacterial and nonbacterial infection included). P ¼ 0.012, OR 5.1. a: sepsis (three patients), pulmonary aspergillosis (three patients), adenoviral cystitis (two patients), and Pneumocyctis carinii (one patient); one patient experienced both sepsis and pulmonary aspergillosis, and another patient had both adenoviral cystitis and pulmonary aspergillosis. b: sepsis (three patients). c: bacterial pneumonia (two patients), sepsis (one patient), and bacterial meningitis (one patient). 20 The numbers of patients with major infection as well as the kind of infection are shown in Table 1 .
Increased risk of infection in MBL polymorphism
Out of 10 patients with major bacterial infections, four were carrying B/B, while three were heterozygote B/A and three were carrying A/A ( Table 1) . As for nonbacterial (virus, fungus, and Pneumocystis carinii) major infection, all of the five cases (six episodes) were homozygous for A, whereas none in the individuals carrying B/A or B/B.
The promoter genotype and the incidence of major infection are shown in Table 1 as well. The H/L and X/Y alleles are known to affect the transcription level of MBL, and the haplotype containing X represents the MBL level similar to those with structural variants at codons 52, 54, and 57. 19 There was no statistically significant difference in the incidence of major bacterial or nonbacterial infections between H/L or X/Y alleles. The individuals carrying the haplotype B/B or B/LXA genetically produce an almost undetectable level of MBL. 19 The individuals carrying this haplotype with insufficient MBL levels (B/B, B/LXA) were 12, four of whom were associated with major bacterial infection. On the other hand, out of 101 individuals without B/B or B/LXA, six had episodes of major bacterial infection. It is thus suggested that the patients with MBL variants, B/B or B/ LXA, may be associated with an increased risk of major bacterial infection compared with those without B/B or B/LXA (33.3 vs 5.9%, P ¼ 0.0016, OR 7.9). Major infections in general (both bacterial and non-bacterial included) were experienced in four out of 12 patients with insufficient genotypes, while nine out of 101 patients carrying sufficient genotypes had episodes of major infection in general (Table 1) . It is therefore demonstrated that the risk of major infection in general was also increased in the patients carrying insufficient MBL alleles (B/B, B/LXA) (33.3 vs 8.9%, P ¼ 0.012, OR 5.1). Our findings are in line with the recent study using MBL null mice that MBL plays a key role in restricting complications associated with Staphylococcal infection. 21 As the coding polymorphism B was most significantly associated with an increased risk of major bacterial infection (Table 1) , we next analyzed the profiles of clinical characteristics of the patients subgrouped according to the presence of B allele. There was no difference in the age at the treatment of HDT and auto-PBSCT between the three groups. Underlying diseases were not skewed between the groups. The duration or incidence of febrile neutropenia and the days needed for neutrophil recovery were not different between the three groups (data not shown).
HDT followed by autologous stem cell transplantation has become one of the most powerful and effective therapeutic tools for some types of malignancies, such as malignant lymphoma and solid tumors. 22 Of the two stem cell sources, peripheral blood and bone marrow, the former is being increasingly used because of easier procedures in collecting stem cells and, more importantly, faster recovery of neutrophils and platelets. [22] [23] [24] However, myeloablative pretransplant chemotherapy usually causes severe neutropenia and thrombocytopenia until engraftment, which occasionally induces life-threatening infections. Several studies have been performed to elucidate risk factors after HDT and autologous stem cell support (auto-PBSCT and auto-BMT); 25, 26 however, genetic risks of the hosts for infection Figure 1 Allele frequencies of MBL allele B in seven different prefectures of Japan. DNA samples of 2623 healthy individuals from seven different prefectures of Japan were analyzed for the allele frequencies of B by using a high-throughput capillary-based SSCP analysis of pooled DNA as described previously. 28 The primers used for the genotyping were as follows: forward primer 5 0 -ATTGGCTTCCCAGG-CAAAGAT-3 0 and the reverse primer 5 0 -GTTAGAACAGCCCAACACGTACC-3 0 . The amplicon size was 321 bp long. The analysis for the difference in the allele frequency between seven different prefectures in Japan was carried out by Z test.
T Horiuchi et al have not been studied. Our study indicated for the first time that a genetic risk factor for major infection is MBL deficiency in patients receiving HDT and auto-PBSCT. Another example of HDT is the condition rescued by allogeneic stem cell transplantation after chemotherapy. It has recently been demonstrated that MBL deficiency is a genetic risk factor of infection in patients treated with HDT and allogeneic stem cell transplantation, 15 which was not confirmed by others. 16 As a variety of complex factors other than MBL polymorphism such as the effect of donor cells should be considered in allogeneic stem cell transplantation, HDT and auto-PBSCT will provide a clearer model to analyze the contribution of MBL polymorphisms to infection after myeloablative treatments. The condition with more reduced dose of chemotherapy, conventional-dose chemotherapy without stem cell support, has been demonstrated to be at an increased risk of infection or prolonged fever in several reports, 13, 14 but not by others. 17, 27 Considering the strong association of MBL polymorphism and major bacterial infection in our patients, it is suggested that the protective role of MBL for infection might be more pronounced in the patients receiving HDT than those with conventional chemotherapy. However, it should be taken into consideration that the controversy about the relationship of MBL deficiency and infection after chemotherapy might be caused, at least in part, by the difference in the patients' profiles, such as underlying diseases, age, ethnicity, and other unknown genetic factors, between these several studies including ours. Further study on clearly defined group of patients will clarify in more detail the relationship of MBL deficiency and infection after chemotherapy.
We next performed a nation-wide study for the incidence of MBL deficiency in a total of 2623 healthy Japanese, which would be the largest study, to our knowledge, for MBL mutation in a single ethnic group (Figure 1) . The allele frequency of B was 0.22570.004 in Hokkaido (n ¼ 402), 0.21270.003 in Akita (n ¼ 397), 0.20670.003 in Niigata (n ¼ 402), 0.19870.003 (n ¼ 320) in Nagano, 0.20270.003 in Aichi (n ¼ 269), 0.21470.003 in Wakayama (n ¼ 407), and 0.21470.003 in Fukuoka (n ¼ 426). There was no statistical difference in the allele frequency between these seven prefectures in Japan. Only the polymorphism at codon 54 was identified, which is in consistent with the previous findings that no polymorphisms at codons 52 and 57 were identified in Japanese. 20, 29 Of the three structural gene polymorphisms at codons 52, 54, and 57, the codon 54 variant has been shown to be predominant in Caucasians (allele frequency 0.11-0.16) and Asians (allele frequency B0.2 in our study), while the codon 57 mutation is mostly identified in Africans in even higher frequencies (0.23-0.29). 4 The codon 52 variant occurs in much lower frequencies in both Caucasians and Africans (allele frequency 0.05 or less). Although MBL deficiency is associated with an increased risk of infection in patients under severe immunosuppression after chemotherapy, the common incidence of MBL variants might indicate some advantage, although not clarified yet, associated with deficiency in the condition of clinical settings without immunosuppression.
We investigated for the first time MBL deficiency as a risk factor for infection in the condition restricted to HDT followed by autologous stem cell transplantation.
Considering the common occurrence of MBL deficiency as well as the increased risk of major infection in our patients with MBL deficiency, the immunosuppressed patients such as those under HDT would be good candidates for MBL reconstitution therapy. In fact, plasma-derived MBL has already been administered to a number of healthy volunteers 30 or selected patients 31 without adverse effects. It would be important to more clearly define subsets of MBL-deficient patients who are at increased risk of infection after chemotherapy and are thus treated effectively with MBL replacement therapy.
